CRANFORD, N.J., Oct. 15, 2019 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced today that the Company
will present at the MicroCap Rodeo on Oct
16th at 9:45-10:15
AM in room 416B. The
conference is being held at the Hilton Austin in Austin, Texas on October 15-16, 2019.
Mr. Leonard Mazur, Chairman, of
Citius Pharmaceuticals will be delivering a presentation, as well
as answering questions from investors. Earlier in the month, Citius
Pharmaceuticals, reached the interim analysis milestone for
Mino-Lok® Phase III pivotal trial. To access Citius Pharmaceuticals
live webcast please use the following link:
https://www.webcaster4.com/Webcast/Page/2134/31874
Citius Pharmaceuticals, Inc. will also be available for
one-on-one meetings. To arrange a meeting with the Company, please
contact Mr. Andrew Scott: ascott@citiuspharma.com.
About MicroCap Rodeo
Bucking the trend of microcap conferences is the first-annual
MicroCap Rodeo in Austin, Texas.
This year's theme: Lassoing the "Best Ideas."
Over two days in October, investors can harness top stocks for
their portfolios. They'll meet with executive management teams from
approximately 50-plus microcap companies across a wide variety of
industries and gain an understanding into the key value drivers and
potential trends for 2020. Complementing the interactive, in-depth
30-minute one-on-one meeting format will be four tracks of company
presentations.
When they're not wrangling great ideas, investors can dig into
delicious Texas food,
entertainment and surprise guests.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives, cancer care and unique prescription
products that use innovative, patented or proprietary formulations
of previously-approved active pharmaceutical ingredients. We seek
to achieve leading market positions by providing therapeutic
products that address unmet medical needs; by using previously
approved drugs with substantial safety and efficacy data, we seek
to reduce the risks associated with pharmaceutical product
development and regulatory requirements. Citius develops products
that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-microcap-rodeo-300938334.html
SOURCE Citius Pharmaceuticals, Inc.